,102 Blinatumomab, which targets CD19 and CD3, was the first FDA-approved BiTE and is now being used to treat various types of refractory and relapsed B cell acute lymphocytic lymphoma (R/R B-ALL), minimal residual disease (MRD+) B-ALL, and R/R diffuse large B cell lymphoma (R/R DLBCL).103. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.